Skip to main content

Table 4 Cost-effectiveness analysis results

From: Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

Drug Stable days per patient Days in relapse per patient Average visits to the emergency room per patient Average number of hospitalizations per patient Economic conclusion*
PP-LAI 325.0 39.0 0.15 0.28 dominant
RIS-LAI 318.6 45.4 0.17 0.33 dominated
  1. LAI long acting injectable, PP paliperidone palmitate, RIS risperidone microspheres, QALY quality adjusted life years.
  2. *Total and incremental costs per patient are onsidered as in Table 3.